These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37980411)

  • 1. PET/CT based cross-modal deep learning signature to predict occult nodal metastasis in lung cancer.
    Zhong Y; Cai C; Chen T; Gui H; Deng J; Yang M; Yu B; Song Y; Wang T; Sun X; Shi J; Chen Y; Xie D; Chen C; She Y
    Nat Commun; 2023 Nov; 14(1):7513. PubMed ID: 37980411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lung cancer with PET/CT-defined occult nodal metastasis yields favourable prognosis and benefits from adjuvant therapy: a multicentre study.
    Deng J; Zhong Y; Wang T; Yang M; Ma M; Song Y; She Y; Chen C;
    Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2414-2424. PubMed ID: 35048154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Predictors of Nodal Metastases in Peripherally Clinical T1a N0 Non-Small Cell Lung Cancer.
    Ghaly G; Rahouma M; Kamel MK; Nasar A; Harrison S; Nguyen AB; Port J; Stiles BM; Altorki NK; Lee PC
    Ann Thorac Surg; 2017 Oct; 104(4):1153-1158. PubMed ID: 28551047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT.
    Park HK; Jeon K; Koh WJ; Suh GY; Kim H; Kwon OJ; Chung MP; Lee KS; Shim YM; Han J; Um SW
    Respirology; 2010 Nov; 15(8):1179-84. PubMed ID: 20573058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of maximum standardized uptake value with occult mediastinal lymph node metastases in cN0 non-small cell lung cancer.
    Lin JT; Yang XN; Zhong WZ; Liao RQ; Dong S; Nie Q; Weng SX; Fang XJ; Zheng JY; Wu YL
    Eur J Cardiothorac Surg; 2016 Nov; 50(5):914-919. PubMed ID: 27113090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Prediction Model to Help with Oncologic Mediastinal Evaluation for Radiation: HOMER.
    Martinez-Zayas G; Almeida FA; Simoff MJ; Yarmus L; Molina S; Young B; Feller-Kopman D; Sagar AS; Gildea T; Debiane LG; Grosu HB; Casal RF; Arain MH; Eapen GA; Jimenez CA; Noor LZ; Baghaie S; Song J; Li L; Ost DE
    Am J Respir Crit Care Med; 2020 Jan; 201(2):212-223. PubMed ID: 31574238
    [No Abstract]   [Full Text] [Related]  

  • 7. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
    Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
    Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high.
    Turkmen C; Sonmezoglu K; Toker A; Yilmazbayhan D; Dilege S; Halac M; Erelel M; Ece T; Mudun A
    Clin Nucl Med; 2007 Aug; 32(8):607-12. PubMed ID: 17667432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-to-liver standard uptake ratio using fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography effectively predict occult lymph node metastasis of non-small cell lung cancer patients.
    Shi YM; Niu R; Shao XL; Zhang FF; Shao XN; Wang JF; Wang XS; Liu B; Yu WJ; Wang YT
    Nucl Med Commun; 2020 May; 41(5):459-468. PubMed ID: 32187163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of Fluorine-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography (¹⁸F-FDG PET/CT) and Tumor Markers to Diagnose Lymph Node Metastasis in Non-Small Cell Lung Cancer (NSCLC): A Retrospective and Prospective Study.
    Zhai X; Guo Y; Qian X
    Med Sci Monit; 2020 Jun; 26():e922675. PubMed ID: 32483109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Endosonographic Mediastinal Lymph Node Staging in Positron Emission Tomography and Computed Tomography Node-Negative Non-Small-Cell Lung Cancer in High-Risk Patients.
    Hegde P; Molina JC; Thivierge-Southidara M; Jain RV; Gowda A; Ferraro P; Liberman M
    Semin Thorac Cardiovasc Surg; 2020; 32(1):162-168. PubMed ID: 31325576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Deep Learning for Prediction of N2 Metastasis and Survival for Clinical Stage I Non-Small Cell Lung Cancer.
    Zhong Y; She Y; Deng J; Chen S; Wang T; Yang M; Ma M; Song Y; Qi H; Wang Y; Shi J; Wu C; Xie D; Chen C;
    Radiology; 2022 Jan; 302(1):200-211. PubMed ID: 34698568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A machine learning tool to improve prediction of mediastinal lymph node metastases in non-small cell lung cancer using routinely obtainable [
    Rogasch JMM; Michaels L; Baumgärtner GL; Frost N; Rückert JC; Neudecker J; Ochsenreither S; Gerhold M; Schmidt B; Schneider P; Amthauer H; Furth C; Penzkofer T
    Eur J Nucl Med Mol Imaging; 2023 Jun; 50(7):2140-2151. PubMed ID: 36820890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography.
    Al-Sarraf N; Aziz R; Gately K; Lucey J; Wilson L; McGovern E; Young V
    Eur J Cardiothorac Surg; 2008 Jan; 33(1):104-9. PubMed ID: 17977738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Unexpected N2 Disease Associated With Clinical T1-2N0-1M0 Non-Small-Cell Lung Cancer.
    Kamigaichi A; Tsutani Y; Mimae T; Miyata Y; Shimada Y; Ito H; Nakayama H; Ikeda N; Okada M
    Clin Lung Cancer; 2021 Mar; 22(2):120-126.e3. PubMed ID: 33485802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Developing a primary tumor and lymph node 18F-FDG PET/CT-clinical (TLPC) model to predict lymph node metastasis of resectable T2-4 NSCLC.
    Wang M; Liu L; Dai Q; Jin M; Huang G
    J Cancer Res Clin Oncol; 2023 Jan; 149(1):247-261. PubMed ID: 36565319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of
    Al-Ibraheem A; Hirmas N; Fanti S; Paez D; Abuhijla F; Al-Rimawi D; Al-Rasheed U; Abdeljalil R; Hawari F; Alrabi K; Mansour A
    BMC Med Imaging; 2021 Mar; 21(1):49. PubMed ID: 33731050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors for Predicting Occult Lymph Node Metastasis in Patients with Clinical Stage I Non-small Cell Lung Cancer Staged by Integrated Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
    Kaseda K; Asakura K; Kazama A; Ozawa Y
    World J Surg; 2016 Dec; 40(12):2976-2983. PubMed ID: 27456499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Occult lymph node metastases in clinical N0/N1 NSCLC; A single center in-depth analysis.
    Beyaz F; Verhoeven RLJ; Schuurbiers OCJ; Verhagen AFTM; van der Heijden EHFM
    Lung Cancer; 2020 Dec; 150():186-194. PubMed ID: 33189983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer.
    Zhang N; Liang R; Gensheimer MF; Guo M; Zhu H; Yu J; Diehn M; Loo BW; Li R; Wu J
    Theranostics; 2020; 10(25):11707-11718. PubMed ID: 33052242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.